Online citations, reference lists, and bibliographies.

Association Of Prothrombin Complex Concentrate Administration And Hematoma Enlargement In Non–vitamin K Antagonist Oral Anticoagulant–related Intracerebral Hemorrhage

Stefan T. Gerner, Joji B Kuramatsu, Jochen A Sembill, Maximilian I. Sprügel, Matthias Endres, Karl Georg Haeusler, Peter Vajkoczy, P A Ringleb, Jan Christoph Purrucker, Timolaos Rizos, Frank Joachim Erbguth, Peter D. Schellinger, Gereon R. Fink, Henning R Stetefeld, Hauke Schneider, Hermann Neugebauer, Joachim Roether, Joseph Classen, Dominik Michalski, Arnd Doerfler, Stefan Schwab, Hagen B Huttner
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To investigate parameters associated with hematoma enlargement in non-vitamin K antagonist oral anticoagulant (NOAC)-related intracerebral hemorrhage (ICH). METHODS This retrospective cohort study includes individual patient data for 190 patients with NOAC-associated ICH over a 5-year period (2011-2015) at 19 departments of neurology across Germany. Primary outcome was the association of prothrombin complex concentrate (PCC) administration with hematoma enlargement. Subanalyses were calculated for blood pressure management and its association with the primary outcome. Secondary outcomes include associations with in-hospital mortality and functional outcome at 3 months assessed using the modified Rankin Scale. RESULTS The study population for analysis of primary and secondary outcomes consisted of 146 NOAC-ICH patients with available follow-up imaging. Hematoma enlargement occurred in 49/146 (33.6%) patients with NOAC-related ICH. Parameters associated with hematoma enlargement were blood pressure ≥ 160mmHg within 4 hours and-in the case of factor Xa inhibitor ICH-anti-Xa levels on admission. PCC administration prior to follow-up imaging was not significantly associated with a reduced rate of hematoma enlargement either in overall NOAC-related ICH or in patients with factor Xa inhibitor intake (NOAC: risk ratio [RR] = 1.150, 95% confidence interval [CI] = 0.632-2.090; factor Xa inhibitor: RR = 1.057, 95% CI = 0.565-1.977), regardless of PCC dosage given or time interval until imaging or treatment. Systolic blood pressure levels < 160mmHg within 4 hours after admission were significantly associated with a reduction in the proportion of patients with hematoma enlargement (RR = 0.598, 95% CI = 0.365-0.978). PCC administration had no effect on mortality and functional outcome either at discharge or at 3 months. INTERPRETATION In contrast to blood pressure control, PCC administration was not associated with a reduced rate of hematoma enlargement in NOAC-related ICH. Our findings support the need of further investigations exploring new hemostatic reversal strategies for patients with factor Xa inhibitor-related ICH. Ann Neurol 2018;83:186-196.
This paper references
10.1056/NEJMoa1502000
Idarucizumab for Dabigatran Reversal.
Charles V. Pollack (2015)
10.1016/S1474-4422(16)00110-1
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
Thorsten Steiner (2016)
10.1161/STROKEAHA.116.013326
Degree and Timing of Intensive Blood Pressure Lowering on Hematoma Growth in Intracerebral Hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial-2 Results.
Cheryl Carcel (2016)
10.1016/S0140-6736(16)32410-2
Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial
Daniel F. Hanley (2017)
10.1001/jamaneurol.2015.3884
Emergency Reversal of Novel Oral Anticoagulants: Help Is on the Way.
Stephan A. Mayer (2016)
10.1007/s12028-015-0213-y
The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage
Jamil R. Dibu (2015)
10.1111/jth.12949
Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal.
Walter Dzik (2015)
10.1093/europace/eut083
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
Hein Heidbuchel (2013)
10.1056/NEJMoa1603460
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage.
A I Qureshi (2016)
10.1160/TH12-05-0319
New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications.
Wolfgang Miesbach (2012)
Early Hemorrhage Growth in Patients With Intracerebral Hemorrhage
ThomasBrott (1997)
10.1212/WNL.0000000000002310
Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
Duncan Wilson (2016)
10.1016/j.jvs.2016.11.019
Andexanet Alfa for Acute Major Bleeding Associated With Factor Xa Inhibitors
Stuart J. Connolly (2017)
10.1160/TH11-01-0052
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.
Francesco Dentali (2011)
10.1161/CIR.0000000000000477
Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
Amish N. Raval (2017)
10.1182/blood-2013-09-529784
How I treat target-specific oral anticoagulant-associated bleeding.
Deborah M. Siegal (2014)
10.1093/europace/euv309
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Hein Heidbuchel (2015)
10.1056/NEJMra1206531
Management of antithrombotic therapy in patients undergoing invasive procedures.
Todd Huntley Baron (2013)
10.1080/01621459.1988.10478722
A Test of Missing Completely at Random for Multivariate Data with Missing Values
Roderick J. A. Little (1988)
10.1161/STROKEAHA.114.006661
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.
Joji Hagii (2014)
10.1186/cc12685
Management of bleeding and coagulopathy following major trauma: an updated European guideline
Donat R Spahn (2013)
10.1136/jnnp-2016-315346
Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials
Grégoire Boulouis (2017)
Rapid reversal of haematoma expansion associated with vitamin K antagonists
Ralf Baron (2016)
10.1097/MBC.0b013e32834f1b0c
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Joachim Stangier (2012)
10.1001/jamaneurol.2015.3682
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants.
Jan Christoph Purrucker (2016)
10.1016/j.jacc.2014.05.065
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Adam Cuker (2014)
10.1161/CIRCULATIONAHA.111.029017
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Elise S. Eerenberg (2011)
10.1007/s12028-015-0222-x
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage
J A Frontera (2015)
10.1177/0962280206074463
Multiple imputation of discrete and continuous data by fully conditional specification
Stef van Buuren (2007)
10.1016/S0140-6736(13)62343-0
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff (2014)
10.1212/01.WNL.0000138428.40673.83
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage
John J. Flibotte (2004)
10.1253/circj.CJ-14-0909
Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
Ginés Escolar (2015)
10.1212/WNL.0b013e3182377e12
Warfarin-related intraventricular hemorrhage
A. Biffi (2011)
10.1001/jama.2015.0846
Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.
Joji B Kuramatsu (2015)
10.1093/eurheartj/ehs408
Acute management of bleeding in patients on novel oral anticoagulants.
Deborah M. Siegal (2013)
10.1056/NEJMc1411800
Use of PER977 to reverse the anticoagulant effect of edoxaban.
Jack Ansell (2014)
10.1016/S1474-4422(06)70495-1
Clinical interpretation and use of stroke scales
Scott E Kasner (2006)
10.1161/STROKEAHA.108.520668
Hematoma growth in oral anticoagulant related intracerebral hemorrhage.
Brett Cucchiara (2008)



This paper is referenced by
10.1111/bjh.15705
Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding
Deepa R J Arachchillage (2019)
10.1016/j.tcm.2019.03.004
A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Truman John Milling (2019)
10.1161/STROKEAHA.118.023492
Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage.
Stefan T. Gerner (2019)
10.1016/j.ajem.2019.12.008
Real-world utilization of andexanet alfa.
Caitlin S. Brown (2019)
10.1161/STROKEAHA.118.021614
Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation–Associated Intracerebral Hemorrhage
Maximilian I. Sprügel (2018)
10.1055/A-0657-7643
Blutdruckmanagement beim akuten Schlaganfall (Ischämie, Blutung, SAB)
Joji B Kuramatsu (2018)
Stroke Prevention and Treatment: New Insights into NOACs and Reversal
(2018)
10.1002/acn3.51001
Hematoma enlargement characteristics in deep versus lobar intracerebral hemorrhage
Jochen A Sembill (2020)
10.1177/1747493019828555
Management of oral anticoagulation after intracerebral hemorrhage
Joji B Kuramatsu (2019)
10.1182/bloodadvances.2018024893
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.
Daniel M. Witt (2018)
10.1007/s00101-018-0474-x
Intensivmedizinische Studien aus 2017/2018
C. J. Reuß (2018)
10.1159/000492395
Peak Troponin I Levels Are Associated with Functional Outcome in Intracerebral Hemorrhage
Stefan T. Gerner (2018)
10.1136/jnnp-2018-319786
Heparin for prophylaxis of venous thromboembolism in intracerebral haemorrhage
Maximilian I. Sprügel (2019)
10.1016/j.nec.2018.06.007
Management of Intraoperative Coagulopathy.
Michal Bar-Natan (2018)
10.1007/s12028-020-00968-6
Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding
Matthew J. Korobey (2020)
10.5603/CJ.2018.0080
Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation - Messages from the 2018 EHRA.
Anna Tomaszuk-Kazberuk (2018)
10.1016/j.jocn.2018.11.032
Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis
Aislyn C. DiRisio (2019)
10.1055/s-0038-1675816
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Raffaele De Caterina (2019)
10.1055/A-0829-8928
Neues beim Schlaganfall unter besonderer Berücksichtigung älterer Patienten
Hans Christoph Diener (2019)
10.1007/s11910-019-0954-7
Patients on NOACs in the Emergency Room
Stefan T. Gerner (2019)
10.1007/s00115-019-0777-4
Intrazerebrale Blutung: „hot topics“
Maximilian I. Sprügel (2019)
10.1007/978-3-030-22445-5_1
Bleeding on Anti-Xa Drugs: “Does All Bleeding Really Stop?”
Colin G. Kaide (2020)
10.1186/s42466-019-0018-0
Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage
Jochen A Sembill (2019)
10.1007/s15005-018-2629-3
Prothrombinkomplex hält das Größenwachstum der Blutung nicht auf
H. -C Diener (2018)
10.1007/s00415-020-09775-7
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place
Dawn Swan (2020)
10.1016/j.hest.2020.01.001
Anticoagulant-associated intracerebral hemorrhage
Andrea Morotti (2020)
10.1186/s13054-019-2492-8
Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage
Joji B Kuramatsu (2019)
10.1007/s12028-019-00866-6
Key Points to Consider When Evaluating Andexxa for Formulary Addition
Harry Peled (2019)
10.1093/eurheartj/ehy136
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Jan Steffel (2018)
10.1007/s12028-018-0635-4
Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants
Christopher Beynon (2018)
Stroke prevention in atrial fibrillation : update with NOAC treatment and the impact of reversal
Dr. Allison Kirsop (2018)
10.1016/J.HEST.2019.06.001
WITHDRAWN: Anticoagulant-associated intracerebral hemorrhage
Andrea Morotti (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar